Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.720
+0.020 (0.43%)
At close: Apr 9, 2026, 4:00 PM EDT
4.570
-0.150 (-3.18%)
After-hours: Apr 9, 2026, 4:21 PM EDT

Neuphoria Therapeutics Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
7.4915.65----
Gross Profit
7.4915.65----
Selling, General & Admin
7.477.778.478.91--
Research & Development
9.859.019.4213.07-11.04-4.32
Other Operating Expenses
1.24-----
Total Operating Expenses
18.5616.7817.8921.98-11.04-4.32
Operating Income
-11.06-1.13-17.89-21.9811.044.32
Interest Income
0.410.170.220.320.010
Other Non-Operating Income (Expense)
-2.920.122.090.14--
Total Non-Operating Income (Expense)
-2.510.292.310.460.010
Pretax Income
-6.08-0.84-15.58-21.52-15.14-6.66
Provision for Income Taxes
-0.42-0.47-0.09-0.14-0.13-0.14
Net Income
-5.66-0.37-15.49-21.38-15.01-6.52
Net Income to Common
-5.66-0.37-15.49-21.38-15.01-6.52
Shares Outstanding (Basic)
321110
Shares Outstanding (Diluted)
321110
Shares Change (YoY)
123.33%95.01%22.38%8.53%73.52%-99.93%
EPS (Basic)
-3.24-0.23-18.62-43.20-29.79-16.19
EPS (Diluted)
-2.61-0.23-18.62-43.20-29.79-16.19
Shares Outstanding
5.381.981.10.680.630.47
Free Cash Flow
-2.360.08-14.68-14.22-15.01-5.65
Free Cash Flow Per Share
-0.910.05-17.64-20.91-23.95-15.66
Gross Margin
100.00%100.00%----
Operating Margin
-147.66%-7.21%----
Profit Margin
-75.59%-2.36%----
FCF Margin
-31.52%0.49%----
EBITDA
-10.4-0.47-17.23-21.2111.85.6
EBITDA Margin
-138.82%-2.98%----
EBIT
-11.06-1.13-17.89-21.9811.044.32
EBIT Margin
-147.66%-7.21%----
Effective Tax Rate
6.86%55.89%0.56%0.65%0.87%2.11%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q